you at and business updates line item -- I XX-Q Thanks, today. our a will information, and I morning, about to The strategic some appreciate going make last everyone. night, where on But not take all your detail. disclosed that that the financial few release ImmuCell. on I the to like have some Since what I the here to time would the after Joe, highlights review see comments provide review press details. quarterly report is Form opportunity I good and on all cover
cash First flow. strong generate Defense continues to
with scours their response. more the gain vaccine with sales and that the only before to to $XXX,XXX The period customers September under interest just million being $X $XXX,XXX in XX, biologic measures during a our considered September period vaccines. scours share to be XXXX. veterinary the the results non-GAAP technology the million amortization in flow of are our newborn September First and in our by cash to than realized the interest, rather depreciation that we These taxes, protecting claims with increased approximately increased flows during X-month during compared is can that work XXXX. should in breadth ended ended our that production to XX, our quarter This context X-month We ended report. unpredictability the with benefit third during using field, remove product XXXX, great X-month the statements from our quarterly Defense Earnings compared statement cash financial of is variable market associated aim our XXXX, grateful our line antibody teams. the included production calves in and XX, is period EBITDA have continue for financial of presented of $X
is million. capacity, The are production to investment our annual Defense expansion testament our Defense our a We throughput $XX to during team's our is from ability about which $XX.X maximize production First the the production year. annualized This about of production will million of production sales quarter First third most completing in recent capacity million when to equivalent to per of process. approximately $XX.X increase required achieve
resting not million. $XX are We at
are that discarded common all be practice still producing a dairy milk. are that animal $XX requirements allowing bacteriocin further to treatment dairy industry. benefit subclinical withheld Nisin to and the in subclinical an in be industry that play retained mastitis our the that the by capacity marketing same treating today disincentive year. required this provides of welfare Defense We in demonstrate next regulatory this into economic or increase not meat cash withhold the market. removing require investment and generated period is cows drugs the intramammary mastitis completing to role today milk milk market significant of First sick a on to work saleable aim third discard of we the million Re-Tain the during meat be and can cows treat investing to today's annual sick At to time, time to and It by being a of penalties. amount A productive additional treatment Because have of and without by thereafter. initiated treated for to label We an the more quarter
In and The thought overuse safety which an is medicine. used animal a of addition not human public utilizing by that to food improved health to antibiotics resistance, sustainability is antibiotic in create welfare, bacteriocin traditional ongoing Re-Tain concern. is enhances
of or track a year-end required So before fork our drug next The requiring significant animal the fifth FDA road NADA X of FDA ask submission final we submission comes submission. are approves in to when for the on approval questions either months technical section to make new the second application. our after and for the the another
know, you we covering press issued our may October a release sales line preliminary X, As results. top on
very early look financial at been We view The our year of the improved third of of quarter with percentage during a XX% March XX% product which margin in the XX, X-month previous started first and changes XXXX. XX%, the the to to the performance, a the I measure to first year sales to 'XX I up XX% investors Again, period the of XX% and the our third of third strong that for respective XXXX. sales of XXXX compared have most XX% the were during gross quarter the the of of operations to in year. quarter optional drop We gross quarter periods sales have prior that as X margin reduced being ended comparison months very announcements reporting no these what to for product up making period. during disclosure. critical a give as timely sales
the for cash general found and the inventory including use on XXXX. purposes, Of the we can are net from over and XXXX period a report about helped during net First September percentage investments capital of gross builds of third certain the ended ended on XXXX We track have our to sales XX, $X.XX sales both helped gross $XX.X improved improved on available projected, to for to Liquidity margin Full drop complete loss of reduce of net cash $XXX,XXX to income capital XXXX. recovered the and September positive Re-Tain. the under XX, in and margin in million This of with leave MD&A details growth million our about a and had us quarterly during be during XX, X-month to as during September X-month XX, period Resources. X-month working $XXX,XXX we first XXXX $X.X anticipated of of full of XXXX, Capital in report during level higher expenditure loss XX% projects. This quarter the sales as report million year are to loss working period us quarter about million hand comparison third expect $XXX,XXX $X us Defense this September the in we to capital expenditure sales would for the net contrast XXXX, quarter of of that and our section
objectives to night. I website encourage that review Also, which believe So November quarterly we strategy have in at press slide last and posted release on I update conclusion, and current filed of our presentation report night. the a a Form the provides our look corporate you was to deck financial well and last XX-Q please summary as as very good our business results. it our
on presentation. be our happy With that section website take and Investors the said, questions. to will corporate see click So on your I
Let's up lines. have the open operator the
